Bristol Myers Squibb Canada (BMS) today announced that Health Canada has approved OPDIVO® SC (nivolumab for subcutaneous injection) across all currently authorized solid tumour indications in ...

Bristol Myers Squibb (BMS) has announced that its PD-1 immune checkpoint inhibitor Opdivo (nivolumab) has been approved by ...

The two businesses working alongside one another will create opportunities to enhance client outcomes, grow together and ...

BMS Group has acquired Istanbul-based Oria Sigorta ve Reasürans Brokerliği, expanding its presence within the Turkish ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity.

After more than two decades as a Big Pharma cancer leader, Nicholas Botwood is swinging into the biotech world as the new ...

A severe weather outbreak across the US midwest over the last few days is likely to have created more than $5 billion in ...

Glucagon-like peptide-1 receptor agonists may cut the risk of obesity-related cancer in patients being treated for diabetes and obesity.